Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Private Equity Round in 2022
Saluda Medical Pty Ltd. is a medical device company focused on developing innovative solutions for the neuromodulation industry. The firm is known for its investigational device, Evoke, which features a closed-loop spinal cord stimulation system. This technology measures the spinal cord's response to stimulation and adjusts the stimulation parameters in real-time to optimize therapeutic outcomes for patients. Founded in 2010 and headquartered in Artarmon, Australia, with additional offices in Minnesota and the United Kingdom, Saluda Medical aims to provide effective treatment for chronic neuropathic pain. The company's unique approach involves monitoring each patient's neural fingerprint to automatically tailor electrical stimulation, ensuring that therapy is customized to meet individual needs. Saluda Medical's commitment to advancing medical technology is underpinned by a strong foundation of scientific research and a team of experienced professionals.
Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Capsule Corporation is an innovative online pharmacy established in 2015 and headquartered in New York, New York. It aims to transform the pharmacy industry by providing a streamlined and personalized experience for patients, healthcare providers, insurers, and manufacturers. Capsule's platform facilitates the online retail of pharmaceutical products through a user-friendly application that focuses on creating customized outcomes for its users. The company emphasizes the importance of human connection in healthcare, recognizing that behind the complexities of the system, there are individuals in need of care and support. Capsule has successfully raised significant funding from prominent investors, enabling it to further its mission of enhancing the pharmaceutical experience through technology and dedicated service.
Private Equity Round in 2021
Kardium Inc. is a medical solutions company based in Burnaby, Canada, specializing in the diagnosis and treatment of atrial fibrillation (AF). Founded in 2007, the company has developed the Globe Mapping and Ablation System, which streamlines AF treatment by integrating single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation into a single catheter. This advanced system aids medical practitioners in diagnosing and treating cardiovascular diseases by providing detailed electrophysiological mapping and the ability to ablate cardiac tissue using radio-frequency energy. Kardium's team comprises experts in medicine, engineering, and research, ensuring a robust foundation for innovation in medical device technology.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Color is a population health technology company founded in 2014 and based in Burlingame, California. It focuses on providing technology and infrastructure for large-scale health initiatives, making advanced healthcare services accessible and cost-effective. Color's Population Genomics Platform offers modular and comprehensive solutions designed to help health systems, employers, and research institutions develop and implement effective population health programs. The company combines innovative technology with specialized laboratory infrastructure and clinical services, facilitating various aspects of health programs, including strategy, participant engagement, genetic testing, data management, and clinical reporting. Color’s partnerships with organizations such as the National Institutes of Health and Verily enhance its capabilities, enabling it to deliver precision health programs that address the challenges of traditional healthcare access and costs.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Alignment Healthcare is dedicated to transforming the complex and confusing process of medical treatment so that every link in the healthcare continuum becomes more efficient, productive and effective. The company partners with providers, health plans and hospitals to create a seamless, fast and easy-to-navigate healthcare experience, which results in happier, healthier and more satisfied patients. Based in Irvine, California, Alignment Healthcare provides partners with an end-to-end continuous care program, including clinical care coordination, risk management capabilities, and IT enablement
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
Color is a population health technology company founded in 2014 and based in Burlingame, California. It focuses on providing technology and infrastructure for large-scale health initiatives, making advanced healthcare services accessible and cost-effective. Color's Population Genomics Platform offers modular and comprehensive solutions designed to help health systems, employers, and research institutions develop and implement effective population health programs. The company combines innovative technology with specialized laboratory infrastructure and clinical services, facilitating various aspects of health programs, including strategy, participant engagement, genetic testing, data management, and clinical reporting. Color’s partnerships with organizations such as the National Institutes of Health and Verily enhance its capabilities, enabling it to deliver precision health programs that address the challenges of traditional healthcare access and costs.
Private Equity Round in 2019
Kardium Inc. is a medical solutions company based in Burnaby, Canada, specializing in the diagnosis and treatment of atrial fibrillation (AF). Founded in 2007, the company has developed the Globe Mapping and Ablation System, which streamlines AF treatment by integrating single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation into a single catheter. This advanced system aids medical practitioners in diagnosing and treating cardiovascular diseases by providing detailed electrophysiological mapping and the ability to ablate cardiac tissue using radio-frequency energy. Kardium's team comprises experts in medicine, engineering, and research, ensuring a robust foundation for innovation in medical device technology.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Guardant Health, Inc. is a precision oncology company based in Redwood City, California, specializing in liquid biopsy tests and analytics for cancer detection and treatment. The company provides advanced testing solutions, including Guardant360, a molecular diagnostic test that analyzes numerous cancer-related genes, and GuardantOMNI, which offers a comprehensive gene panel for immuno-oncology research. Additionally, Guardant Health has developed LUNAR-1 for detecting minimal residual disease in cancer survivors and is working on LUNAR-2 for early cancer detection in high-risk individuals. The company also supports biopharmaceutical companies and medical institutions by offering companion diagnostic development, clinical trial referrals, and liquid biopsy testing services. Guardant Health's innovations aim to address unmet needs in oncology and enhance patient health through advanced technology and research collaborations. The company was incorporated in 2011 and continues to lead in liquid-based cancer testing for both clinical and research applications.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Dr. Lal PathLabs, founded in 1949 by Dr. S.K. Lal, a pioneer in pathology, has established itself as a leading clinical pathology laboratory in India. Originally the first of its kind in Delhi and Northern India, the organization has expanded its services to include comprehensive diagnostic offerings in pathology and radiology. Dr. Lal PathLabs operates multiple laboratories that conduct a wide range of tests across various disciplines such as biochemistry, hematology, histopathology, microbiology, immunology, and virology. These diagnostic services play a crucial role in disease prevention, monitoring, and treatment, ultimately contributing to improved health outcomes. While the company primarily generates its revenue in India, it also operates in several other countries, reflecting its growing international presence in the healthcare sector.
Editas Medicine is a clinical-stage company focused on developing innovative genome editing therapeutics to address serious diseases at the genetic level. Established in 2013 and headquartered in Cambridge, Massachusetts, with an additional site in Boulder, Colorado, the company leverages its proprietary CRISPR/Cas9 technology to create precise and corrective molecular modifications. This approach utilizes a protein-RNA complex, which includes the Cas9 enzyme and a guide RNA, to target and repair specific DNA sequences. Editas Medicine aims to translate its advances in genome editing into transformative human therapies, supported by a robust portfolio of patents and intellectual property that underpins its foundational technologies.
Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products.
AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine).
AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products.
AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).
Doximity is a digital platform that serves as the largest professional medical network in the United States, connecting over 70 percent of U.S. physicians. Founded in 2011 and based in San Francisco, Doximity provides a suite of tools designed specifically for medical professionals, including physicians, nurse practitioners, physician assistants, and registered nurses. The platform facilitates secure communication among healthcare providers, enabling them to collaborate on patient care, conduct virtual visits, and stay informed about the latest medical news and research. Additionally, Doximity offers resources to help medical professionals manage their careers effectively.
Castlight Health is dedicated to simplifying the healthcare experience and promoting healthier, more productive lives. Its health navigation platform integrates with various health vendors, benefits resources, and plan designs, creating a comprehensive application that addresses diverse health needs. By tailoring guidance to individual profiles, Castlight assists users, whether they are healthy, managing chronic conditions, or seeking medical care, in accessing optimal resources. The company aims to help organizations manage rising healthcare costs and enhance the value of their benefits investments. Since its inception, Castlight has introduced innovative solutions such as data-driven price transparency tools and a consumer-friendly wellbeing platform. Currently, it serves millions of users and partners with numerous large employers, positioning itself as a key player in the healthcare sector. Castlight is headquartered in San Francisco.
Aspect Medical Systems specializes in brain monitoring technology that measures the direct effects of anesthetics and sedatives on patient consciousness. The company is recognized as a pioneer in this field, having developed proprietary systems, including BIS monitors and patient sensors, that provide critical information for clinicians. These monitoring systems enable healthcare professionals to assess and manage patients' levels of consciousness in various settings, such as operating rooms, intensive care units, and during procedural sedation. By offering insights into the effects of drugs on the brain, Aspect Medical Systems aims to enhance patient care quality and optimize the effectiveness and safety of anesthesia administration.